Carboplatin: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Howard C. Berkowitz
No edit summary
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
In [[oncology]], '''carboplatin''' is a [[antineoplastic agent]] that is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref>
{{subpages}}
{{TOC|right}}
In [[oncology]], '''carboplatin''' is a [[antineoplastic agent]] that is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref> As compared to [[cisplatin]], carboplatin has equal ([[lung cancer]], [[ovarian cancer]]) or less ([[germ cell tumor]]s, [[bladder cancer]], [[head and neck cancer]]) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> When considered in veterinary oncology, carboplatin can be used in cats but cisplatin is fatal to felines.


As compared to [[cisplatin]], carboplatin has equal ([[lung cancer]], [[ovarian cancer]]) or less ([[germ cell tumor]]s, [[bladder cancer]], [[head and neck cancer]]) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678
Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the [[World Health Organization]] calls "other neoplastic agents", specifically class  L01XA. <ref>WHO drug database search tool, [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XA]</ref>
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


==History==
==History==
In the United States, it was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1989.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=019880 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076039 Drugs@FDA]. U S Food and Drug Administration</ref>
In the United States, it was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1989.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=019880 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076039 Drugs@FDA]. U S Food and Drug Administration</ref>
 
==Indications==
===Human===
In the U.S., it is only approved for [[ovarian carcinoma]], but common off-label uses include:<ref>{{citation
| url = http://www.medscape.com/druginfo/dosage?drugid=4551&drugname=Carboplatin+IV&monotype=default
| title = Carboplatin
| publisher = American Society of Health System Pharmacists}}</ref>
*[[carcinoma]]s
**[[endometrial carcinoma]]
**[[neuroendocrine prostate carcinoma]]
**[[small cell lung carcinoma]]
**metastatic and locally advanced [[breast carcinoma]]
*[[leukemia]]s
** [[acute myeloid leukemia]]
*Unspecified histology
**Malignant Tumor of Cervix
**Malignant Tumor of Head and Neck
**Malignant Tumor of Urinary Bladder
**Non-Small Cell Lung Cancer
**Refractory Malignant Tumor of Testis
*Lymphoma
**Progressive Diffuse Large B-Cell Lymphoma
*[[Sarcoma]]
**Refractory [[Ewing's sarcoma]]
**Refractory [[osteosarcoma]]
*Seminoma of Testis,
===Veterinary===
It is usually the second chemotherapeutic agent used in [[feline squamous cell carcinoma]].
==Dosage==
==Dosage==
Carboplatin may be dosed by the Calvert formula:<ref name="pmid2681557">{{cite journal| author=Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al.| title=Carboplatin dosage: prospective evaluation of a simple formula based on renal function. | journal=J Clin Oncol | year= 1989 | volume= 7 | issue= 11 | pages= 1748-56 | pmid=2681557  
Carboplatin may be dosed by the Calvert formula:<ref name="pmid2681557">{{cite journal| author=Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al.| title=Carboplatin dosage: prospective evaluation of a simple formula based on renal function. | journal=J Clin Oncol | year= 1989 | volume= 7 | issue= 11 | pages= 1748-56 | pmid=2681557  
Line 16: Line 44:


==References==
==References==
<references/>
{{reflist|2}}

Latest revision as of 07:06, 27 June 2010

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Carboplatin&printable=yes
This editable Main Article is under development and subject to a disclaimer.

In oncology, carboplatin is a antineoplastic agent that is an "organoplatinum compound that possesses antineoplastic activity."[1] As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2] When considered in veterinary oncology, carboplatin can be used in cats but cisplatin is fatal to felines.

Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the World Health Organization calls "other neoplastic agents", specifically class L01XA. [3]

History

In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[4] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[5]

Indications

Human

In the U.S., it is only approved for ovarian carcinoma, but common off-label uses include:[6]

Veterinary

It is usually the second chemotherapeutic agent used in feline squamous cell carcinoma.

Dosage

Carboplatin may be dosed by the Calvert formula:[7]

External links

The most up-to-date information about Carboplatin and other drugs can be found at the following sites.


References

  1. ↑ Anonymous (2024), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
  3. ↑ WHO drug database search tool, [1]
  4. ↑ Drugs@FDA. U S Food and Drug Administration
  5. ↑ Drugs@FDA. U S Food and Drug Administration
  6. ↑ Carboplatin, American Society of Health System Pharmacists
  7. ↑ Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. (1989). "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.". J Clin Oncol 7 (11): 1748-56. PMID 2681557.
Retrieved from "https://citizendium.org/wiki/index.php?title=Carboplatin&oldid=684320"